The state-of-the-art therapeutic paradigms against sepsis

被引:0
作者
Saha, Ishita [1 ]
Bag, Neelanjana [3 ]
Roy, Shubham [2 ]
Ullah, Zia [2 ]
Bardhan, Souravi [3 ]
Karmakar, Parimal [1 ]
Das, Sukhen [3 ]
Guo, Bing [2 ]
机构
[1] Department of Life Science and Biotechnology, Jadavpur University, Kolkata
[2] School of Science, Shenzhen Key Laboratory of Flexible Printed Electronics Technology, Shenzhen Key Laboratory of Advanced Functional Carbon Materials Research, Harbin Institute of Technology, Shenzhen
[3] Department of Physics, Jadavpur University, Kolkata
来源
Smart Materials in Medicine | 2024年 / 5卷 / 03期
关键词
Drug delivery; Dynamic therapy; Exosome; Inflammation; Liposome; Nanoparticle; Sepsis;
D O I
10.1016/j.smaim.2024.08.005
中图分类号
学科分类号
摘要
Sepsis frequently leads to life-threatening organ failure due to an in appropriate response by the body to bacterial, viral, and fungal infections. In recent years, there has been an increasing interest in using nanoparticles to develop biomarkers and drug delivery systems that have significantly improved the treatment of infectious diseases. Herein, we update the most recent development of nanoparticle-based therapeutics for sepsis treatment. This article begins with a brief overview of how sepsis is triggered and its associated diseases. It also explores the differences between traditional and modern treatment approaches. Afterward, the reasons for embracing nanotechnology-based therapies for sepsis are summarized, including their ability to reduce inflammation, provide antioxidant effects, regulate cell signaling pathways, manage reactive oxygen and nitrogen species (RONS) production, control autophagy and apoptosis, clear lipopolysaccharides (LPS) from the blood, inhibits the formation of cell-free DNA and cytokine storms. Furthermore, the special emphasis is on updating the use of nanotechnology-mediated drug delivery systems, such as nanoparticles, liposomes, and exosomes, in the treatment of sepsis caused by various microorganisms. Moreover, we also discuss polymer mediated therapy and some dynamic therapeutic aspects in septecemia disease. In addition, the article highlights the challenges and a limitation associated with using drug delivery for sepsis treatment and expresses the hope that this review will accelerate the development of more effective sepsis therapies and facilitate the transition from research to practical clinical application. © 2024 The Authors
引用
收藏
页码:425 / 446
页数:21
相关论文
共 138 条
[1]  
Hall M.J., Williams S.N., DeFrances C.J., Golosinskiy A., Inpatient Care for Septicemia or Sepsis: a Challenge for Patients and Hospitals, pp. 1-8, (2011)
[2]  
Lin G.-L., McGinley J.P., Drysdale S.B., Pollard A.J., Epidemiology and immune pathogenesis of viral sepsis, Front. Immunol., 9, (2018)
[3]  
Menon K., Schlapbach L.J., Akech S., Argent A., Chiotos K., Chisti M.J., Hamid J., Et al., Pediatric sepsis definition—a systematic review protocol by the Pediatric Sepsis Definition Taskforce, Critical care explorations, 2, 6, (2020)
[4]  
Fink M.P., Shaw Warren H., Strategies to improve drug development for sepsis, Nat. Rev. Drug Discov., 13, 10 13, pp. 741-758, (2014)
[5]  
Bray M., Mahanty S., Ebola hemorrhagic fever and septic shock, J. Infect. Dis., 188, pp. 1613-1617, (2003)
[6]  
Lin T., Qin T., Jiang S., Zhang C., Wang L., Anti-inflammatory and anti-biotic drug metronidazole loaded ZIF-90 nanoparticles as a pH responsive drug delivery system for improved pediatric sepsis management, Microb. Pathog., 176, (2023)
[7]  
Rudd K.E., Johnson S.C., Agesa K.M., Shackelford K.A., Tsoi D., Kievlan D.R., Colombara D.V., Ikuta K.S., Kissoon N., Finfer S., Fleischmann-Struzek C., Machado F.R., Reinhart K.K., Rowan K., Seymour C.W., Watson R.S., West T.E., Marinho F., Hay S.I., Lozano R., Lopez A.D., Angus D.C., Murray C.J.L., Naghavi M., Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study, Lancet, 395, pp. 200-211, (2020)
[8]  
Guarino M., Perna B., Eleonora Cesaro A., Maritati M., Domenico Spampinato M., Contini C., De Giorgio R., 2023 update on sepsis and septic shock in adult patients: management in the emergency department, J. Clin. Med., 12, 9, (2023)
[9]  
Neilson H.K., Fortier J.H., Finestone P.J., Ogilby C.M., Liu R., Bridges E.J., Garber G.E., Diagnostic delays in sepsis: lessons learned from a retrospective study of Canadian medico-legal claims, Crit Care Explor, 5, (2023)
[10]  
Xu M.-X., Ge C.-X., Qin Y.-T., Gu T.-T., Lou D.-S., Li Q., Hu L.-F., Tan J., Multicombination approach suppresses listeria monocytogenes-induced septicemia-associated acute hepatic failure: the role of iRhom2 signaling, Adv. Healthcare Mater., 7, 17, (2018)